scholarly journals MONITORING OF FUNCTIONAL PARAMETERS IN THE PATIENTS WITH EARLY STAGE OF AGE-RELATED MACULAR DEGENERATION

2017 ◽  
Vol 14 (3) ◽  
pp. 260-267 ◽  
Author(s):  
I. A. Gndoyan ◽  
A. V. Petrayevsky ◽  
N. A. Kuznetsova ◽  
A. I. Dyatchina
Keyword(s):  
Macular Degeneration ◽  
Early Stage ◽  
Age Related Macular Degeneration ◽  
Functional Parameters ◽  
Age Related

scholarly journals Efficacy of Psychiatric Treatment to Treat a Specific Phobia of Intravitreal Injections in a Patient with Neovascular Age-Related Macular Degeneration

2021 ◽  
pp. 48-56
Author(s):  
Atsuta Ozaki ◽  
Hisashi Matsubara ◽  
Masahiko Sugimoto ◽  
Manami Kuze ◽  
Mineo Kondo ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Macular Edema ◽  
Psychiatric Treatment ◽  
Early Stage ◽  
Behavioral Therapy ◽  
Specific Phobia ◽  
Age Related Macular Degeneration ◽  
Intravitreal Injections ◽  
Anti Vegf ◽  
Age Related

Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) is essential for the treatment of macular diseases such as wet age-related macular degeneration and macular edema. Although continued treatment is needed to maintain good vision, some patients cannot continue such injections for various reasons, including specific phobias. Here, we report a case of a patient with a specific phobia of intravitreal injections who could resume treatment after undergoing combined drug and cognitive-behavioral therapy (CBT). A 74-year-old Japanese man diagnosed with retinal angiomatous proliferation by fluorescein angiography and indocyanine green angiography was treated with intravitreal anti-VEGF injection. However, at 8 months after the first treatment, he became difficult to treat because of a phobia of injections. He was treated with photodynamic therapy, but his macular edema did not improve. After a psychiatric consultation, he was diagnosed with a specific phobia of intravitreal injections. Combined drug and CBT enabled him to resume receiving intravitreal injections. This case demonstrates that a specific phobia of intravitreal injections may benefit from combined drug and CBT. In this regard, some patients with high anxiety and fear of intravitreal injections should be referred to a psychiatrist at an early stage.

Epilutein for Early-Stage Age-Related Macular Degeneration: A Randomized and Prospective Study

2017 ◽  
Vol 58 (4) ◽  
pp. 231-241 ◽  
Author(s):  
Raimondo Forte ◽  
Lucia Panzella ◽  
Ida Cesarano ◽  
Gilda Cennamo ◽  
Thomas Eidenberger ◽  
...  
Keyword(s):  
Prospective Study ◽  
Macular Degeneration ◽  
Early Stage ◽  
Age Related Macular Degeneration ◽  
Age Related

scholarly journals Photoreceptor layer thinning is an early biomarker for age-related macular degeneration development: Epidemiological and genetic evidence from UK Biobank optical coherence tomography data

2021 ◽  
Author(s):  
Seyedeh Maryam Zekavat ◽  
Sayuri Sekimitsu ◽  
Yixuan Ye ◽  
Hongyu Zhao ◽  
Tobias Elze ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Macular Degeneration ◽  
Early Stage ◽  
Age Related Macular Degeneration ◽  
Retinal Layer ◽  
Polygenic Risk Score ◽  
Uk Biobank ◽  
Polygenic Risk ◽  
Age Related ◽  
Clinical Biomarker

AbstractIntroductionAge-related macular degeneration (AMD) is a blinding condition for which there is currently no early-stage clinical biomarker. AMD is characterized by thinning of the outer retina and drusen formation leading to thickening of the Bruch’s membrane and RPE complex, but the timing between these two events, as well as the role of genetic variants in these processes, are unclear. Here, we jointly analyzed genomic, electronic health record, and optical coherence tomography (OCT) data across 44,823 individuals from the UK Biobank to characterize the epidemiological and genetic associations between retinal layer thicknesses and AMD.MethodsThe Topcon Advanced Boundary Segmentation algorithm was used for automated retinal layer segmentation. We associated 9 retinal layer thicknesses with prevalent AMD (present at enrollment) in a logistic regression model, and with incident AMD (diagnosed after enrollment) in a Cox proportional hazards model. Next, we tested the association of AMD-associated genetic alleles, individually and as a polygenic risk score (PRS), with retinal layer thicknesses. All analyses were adjusted for age, age2, sex, smoking status, and principal components of ancestry.ResultsPhotoreceptor segment (PS) thinning was observed throughout the lifespan of individuals analyzed and accelerated at age 45, while retinal pigment epithelium and Bruch’s membrane complex (RPE+BM) thickening started after age 57. Each standard deviation (SD) of PS thinning and RPE+BM thickening were associated with prevalent AMD (PS: OR 1.37, 95% CI 1.25-1.49, P=2.5×10−12; RPE+BM: OR=1.34, 95% CI 1.27-1.41, P=8.4×10−28) and incident AMD (PS: HR 1.35, 95% CI 1.23-1.47, P=3.7×10−11; RPE+BM: HR 1.14, 95% CI 1.06-1.22, P=0.00024). An AMD polygenic risk score (PRS) was associated with PS thinning (Beta -0.21 SD per 2-fold genetically increased risk of AMD, 95% CI -0.23 to -0.19, P=2.8×10−74), and its association with RPE+BM was U-shaped (thinning with AMD PRS<92nd percentile and thickening with AMD PRS>92nd percentile suggestive of drusen formation). The loci with strongest support were AMD risk-raising variants CFH:rs570618-T, CFH:10922109-C, and ARMS2/HTRA1:rs3750846-C on PS thinning, and SYN3/TIMP3:rs5754227-T on RPE+BM thickening.ConclusionsEpidemiologically, PS thinning precedes RPE+BM thickening by decades, and is the retinal layer most strongly predictive of future AMD risk. Genetically, AMD risk variants are associated with decreased PS thickness. Overall, these findings support PS thinning as an early-stage clinical biomarker for future AMD development.

scholarly journals Does Matrix Metalloproteinase-3 Polymorphism Play a Role in Age-Related Macular Degeneration in Patients With Myocardial Infarction?

Medicina ◽  
2012 ◽  
Vol 48 (8) ◽  
pp. 60 ◽  
Author(s):  
Rasa Liutkevičienė ◽  
Diana Žaliaduonytė-Pekšienė ◽  
Dalia Žaliūnienė ◽  
Olivija Gustienė ◽  
Vytautas Jašinskas ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Gene Polymorphism ◽  
Matrix Metalloproteinase ◽  
Macular Degeneration ◽  
Early Stage ◽  
Gene Promoter ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Matrix Metalloproteinase 3 ◽  
Age Related

Objective. The aim of our study was to determine if the genotype of the matrix metalloproteinase- 3 (MMP-3) gene might carry the risk of age-related macular degeneration (ARMD) in patients with myocardial infarction. Material and Methods. A total of 499 patients with an acute myocardial infarction or with a history of myocardial infarction were enrolled into the study. They were subdivided into 2 groups: 273 patients with ARMD and 226 patients without ARMD. The control group comprised 560 persons from a random sample of the Lithuanian population. DNA was analyzed using real-time polymerase chain reaction to genotype polymorphism 5A/6A at a position –1171 of the MMP-3 gene promoter. Results. Of the 499 patients with myocardial infarction, 47% had early-stage ARMD. The patients with ARMD were older than the patients in the group without ARMD (62.1±10.8 vs. 59.6±11.1, P<0.01). The analysis of MMP-3 gene polymorphism did not reveal any differences in the distribution of 5A/5A, 5A/6A, and 6A/6A genotypes between the ARMD group, non-ARMD group, and the control group (24.2%, 52.5%, and 23.3% in the ARMD group; 28.7%, 51.9%, and 19.4% in non-ARMD group; and 25.7%, 49.3% and 25.0%, in the control group, respectively). Conclusions. MMP-3 gene polymorphism had no predominant effect on the development of ARMD in patients with myocardial infarction.

scholarly journals Supplementation with three macular carotenoids in patients with early stage age-related macular degeneration

2019 ◽  
Vol 72 (9-10) ◽  
pp. 291-296
Author(s):  
Sandra Jovanovic ◽  
Sofija Davidovic ◽  
Aleksandar Miljkovic ◽  
Milica Atanackovic-Krstonosic ◽  
Darija Sazdanic ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Contrast Sensitivity ◽  
Early Stage ◽  
Visual Quality ◽  
Age Related Macular Degeneration ◽  
Visual Performance ◽  
Early Age ◽  
Age Related ◽  
Glare Sensitivity

Introduction. Macula lutea is the central part of the retina and it houses carotenoid macular pigments - lutein, zeaxanthin, and meso-zeaxanthin. It is considered that carotenoids can prevent or slow down the progression of the early age-related macular degeneration in some patients. Therefore, the aim of this study was to examine the effects of supplementation with all three macular pigments on vision quality in patients with early agerelated macular degeneration. Material and Methods. This prospective study included 15 patients (25 eyes in total) with early age-related macular degeneration. All visual tests - visual acuity, glare sensation and contrast sensitivity, were performed at baseline and after 6 months of continuous supplementation with 10 mg lutein, 2 mg zeaxanthin, and 10 mg mesozeaxanthin. Results. The results showed that glare sensitivity improved in 20% of cases. Most of the examined eyes (76%) presented without visual acuity deterioration. Similar results were obtained for the contrast sensitivity test, where in 80% of cases vision quality remained stable or improved. There were no statistically significant differences between average values of examined parameters at baseline and after 6 months of supplementation. Conclusion. In most of the examined eyes (over 75%) visual quality remained stable or improvement of measured parameters was observed. This type of supplementation may improve visual performance or its preservation in patients with early age-related macular degeneration.

Sign in / Sign up

Export Citation Format

Share Document